Jaguar Health Advances Crofelemer Trials for Rare Diarrheal Diseases
• Jaguar Health has initiated multiple clinical trials to evaluate crofelemer for treating rare diarrheal diseases, including Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Microvillus Inclusion Disease (MVID).
• Crofelemer, a plant-based drug, has received Orphan Drug Designation from the FDA and EMA for both SBS-IF and MVID, potentially expediting its development and market access.
• Clinical trials include investigator-initiated studies and Phase 2 trials across the US, EU, and MENA regions, with initial proof-of-concept results expected as early as H1 2025.
• These trials aim to address unmet needs in treating severe diarrhea and malabsorption in pediatric and adult patients, potentially leading to reimbursed early patient access in certain EU countries.
© Copyright 2025. All Rights Reserved by MedPath